The latest trend gaining momentum in the tuberculosis drug market is focus on development of shorter TB drug regimens. MDR-TB needs a treatment course of second-line drugs over 18 months or more, which is quite higher than the standard six months of treatment with first-line TB drugs. Since last 5-7 years, the R&D efforts have been accelerated to reduce this elongated timeline and conventional treatment regimen for MDR-TB. 更多
